Superior Planning, LLC’s CRISPR Therapeutics CRSP Stock Holding History

Superior Planning, LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.99K	Buy	+36	New	+$1.94K	﹤0.01%	1561

Other funds holding CRSP

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Superior Planning, LLC's CRSP Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 36 shares worth $1.99K. The stake represents ﹤0.01% of the portfolio and ranks #1561 among its holdings.

340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Superior Planning, LLC held 36 shares of CRISPR Therapeutics worth $1.99K as of Q3 2026.
CRISPR Therapeutics was a new Superior Planning, LLC position in Q3 2026.
CRISPR Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1561 holding.
340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.